Pegfilgrastim Biosimilar Size Market Is Expected To Witness An Upswing In The Future

images 27

Pegfilgrastim is developed by PEGylating the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. Pegfilgrastim was first launched by Amgen Inc. as Neulasta in 2002. Later, several biosimilars of pegfilgrastim were launched in the market.

Pegfilgrastim is used as a supportive oncology drug to treat chemotherapy- and/or radiotherapy-induced neutropenia in cancer patients. With more than ten pegfilgrastim biosimilars available in the market and over 5 under development, the pegfilgrastim biosimilar size market is expected to witness an upswing in the future.

Click Here To get a Sample Report (Including Full TOC, Table & Figures):-https://www.factmr.com/connectus/sample?flag=S&rep_id=1494

Key Segments of Pegfilgrastim Biosimilar Market

Fact.MR’s study on the pegfilgrastim biosimilar market offers information divided into two important segments-distribution channel and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories, for the better understanding of readers.

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

Region

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Pegfilgrastim Biosimilar Market: Key Players

The pegfilgrastim biosimilar market is significantly consolidated and competitive in nature. Many small and large pharmaceutical companies have developed this biosimilar. Key players operating in the market are Coherus Biosciences, Mylan N.V., Biocon, and Novartis AG (Sandoz). These companies have launched pegfilgrastim biosimilars and are bolstered with partnerships and collaborations for expanding their market presence, globally.

Other players in the market are Pfizer Inc, Green Cross Corp, Accord healthcare, Intas Pharmaceuticals Ltd, and Zydus Cadila. These players are focused on strategic collaborations & partnerships and investments in research & development for developing novel biosimilar platforms.

The Analyst’s Viewpoint

“Key players should target emerging markets along with developed markets to make the access of affordable biosimilar therapeutics easy for a large patient population, and, in turn, expand their global footprints.”

Leave a Reply

Your email address will not be published.